seeking alpha this time went to their bench for th
Post# of 147954
is the article goes pretty big mentioning rosenbaum and the 13d in detail all written from india.what really bothers me is last year avisol capital partners praised the nash results of akero therapeutics but imo our 350mg nash is superior to akero.therefore i doubt they even bothered to read the data for our 350 mg nash.
https://in.linkedin.com/in/avisol-capital-partners-4b1ba2139